Daniel Carrasco is a Dermatology physician affiliated with Houston Institute for Clinical Research. OpenAlex indexes 35 publications with 519 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3705 Medical Pkwy
Ste 340
Austin, TX 787051019
Telephone
512-454-3781Registry record last updated 19 Jan 2010.
Industry payments
40 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202562 payments$58,994openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202568 payments$56,020openpaymentsdata.cms.gov ↗
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202540 payments$35,717openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
76.2%Interleukin-23 Antagonist75.2%Tildrakizumab100%Tremfya0%Part D + Part B<11 patientsPorphyrin Precursor0.6%Aminolevulinic acid hcl100%Part B, office-administered≥25 patients+ 1 more class in this area
Dermatology
10.9%Corticosteroid8.7%Triamcinolone acetonide67%Triamcinolone Acetonide33%Part D + Part B≥104 patientsAllylamine Antifungal0.8%Terbinafine Hcl100%Part D≥23 patients+ 4 more classes in this area
Anti-infectives
8%Tetracycline-class Drug4.7%Doxycycline Hyclate96%Oracea4%Part D<11 patientsAzole Antifungal1.5%Ketoconazole75%Fluconazole25%Part D≥36 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Successful treatment of renal cell carcinoma with paraneoplastic nephrotic syndrome: a case report
Frontiers in Medicine
2025 - 529 Exploratory analysis of a phase 2 multicenter study evaluating local immune activation in the tumor microenvironment 12 weeks post VP-315, an investigational therapy for basal cell carcinoma (BCC)
Regular and Young Investigator Award Abstracts
2025 - Benefits of Routine Screening for Renal Cell Carcinoma of Native Kidney in Renal Transplant Recipients
Transplantation Proceedings
2023 - Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis.
PubMed
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Frank Lanza, MD
Houston Institute for Clinical Research
Suzanne Bruce, MD
Houston Institute for Clinical Research
Frank Wellborne, DO
Houston Institute for Clinical Research
Cindy Berthelot, MD
Houston Institute for Clinical Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”